Introduction:Neoadjuvant chemo-immunotherapy is one of the standard treatment options for resectable stage II-III non-small cell lung cancer (NSCLC). However, this treatment yielded insufficient local control in the CheckMate 8...
[11] Pinheiro LC, Reeve BB. Investigating the prognostic ability of health-related quality of life on survival: a prospective cohort study of adults with lung cancer[J]. Support Care Cancer, 2018, 26(11):3925-3932. [...
In terms of cancer- related mortality, it is clear that lung cancer is the leading cause of death in men and the second in women. Non-small cell lung cancer (NSCLC) accounts for the vast majority of cases (85%) and only one of three patients is a candidate for curative treatment with...
Stacy knows her family has her back. Her husband and sisters showed unwavering support, especially with advanced non-small cell lung cancer and treated with OPDIVO + YERVOY. “Utilize everything at your disposal...then come up with the best treatment between you and your doctor." ...
See how OPDIVO® (nivolumab) + YERVOY® (ipilimumab) performed in a clinical trial as first-line treatment for adults with advanced non-small cell lung cancer that tested positive for PD-L1 . Please see Indication and Important Safety Information.
TTFields Therapy Earns EU Approval in Metastatic Non–Small Cell Lung Cancer Russ Conroy April 24th 2025 Article Data from the phase 3 LUNAR trial support the Conformité Européenne Mark for tumor treating fields in metastatic non–small cell lung cancer....
It’s important to be as healthy as you can be, both mentally and physically, to meet the challenges of non-small-cell lung cancer. Here’s how.
Nowadays,advanced non-small cell lung cancer (NSCLC) is still an incurable disease.However,recent researches on maintenance therapy have led to considerable progress.Recently,pemetrexed and erlotinib have been approved for maintenance chemotherapy by both the U.S.Food and Drug Administration and ...
ofthesecasesarenon-small-celllungcancer(NSCLC)(2).theuseofadjuvantchemotherapyinstageIBdisease(5). InfunctionallyfitpatientswithlocalizeddiseasesurgicalAtotalof340patientswererandomlyassignedtoadjuvant resectionremainsthetreatmentofchoice(2).Thereischemotherapyorobservation.Therewasnosignificant ...
To evaluate the association between irAEs and atezolizumab efficacy in patients with advanced non–small cell lung cancer (NSCLC) using pooled data from 3 phase 3 ICI studies. 利用3项ICI研究的汇总数据,评估晚期非小细胞肺癌(NSCLC)患者的irAEs与阿特唑仑疗效之间的关系。